Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novo-Lumen
Eindhoven, North Brabant, Netherlandsnovolumen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NovoLumen was a medical technology company that developed advanced interventional tools for the treatment of complex vascular diseases. The company's flagship product was a smart guidewire that integrated Optical Coherence Tomography (OCT) to provide real-time, high-resolution imaging from within the blood vessel. This technology was designed to assist interventional cardiologists and vascular surgeons in navigating and crossing Chronic Total Occlusions (CTO), which are complete blockages of arteries that are difficult to treat with standard techniques. By improving visualization at the tip of the guidewire, NovoLumen aimed to increase the success rate of minimally invasive procedures and reduce the need for more invasive bypass surgeries.
- Therapeutic areas
- Cardiovascular
- Modalities
- Device
- Industry
- Medical Imaging
Beyond the preview
Go deeper on Novo-Lumen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novo-Lumen.